Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer Inc.    PFE

PFIZER INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

UK regulator says it did not cut any corners to approve Pfizer vaccine

12/02/2020 | 05:27am EST

LONDON (Reuters) - Britain's medicines regulator did not cut any corners in the rolling review process that led it to approve the Pfizer vaccine against COVID-19, the regulator's chief executive said on Wednesday, describing the review as thorough and rigorous.

"It's very clear that separate teams have been working in parallel to deliver the most rigorous review of this vaccine. No corners have been cut," June Raine said.

"Our expert scientists and clinicians have worked round the clock, carefully, methodically, poring over tables and analyses and graphs on every single piece of data, hundreds, over a thousand pages of data and, absolutely critically, analysing the pre-clinical evidence, the clinical trials, the manufacturing and quality controls, and then down to the final sampling."

(Reporting by Guy Faulconbridge and Estelle Shirbon; editing by William James)


© Reuters 2020
All news about PFIZER INC.
07:28aEXCLUSIVE : Pharma distributors in talks with U.S. for cut of COVID-19 vaccine s..
RE
06:17aASTRAZENECA : Japan To Secure AstraZeneca's COVID-19 Vaccine From Domestic Sourc..
MT
04:51aPFIZER INC. : - In Vitro Studies Demonstrate Pfizer and BioNTech COVID-19 Vaccin..
AQ
01:33aPRESS RELEASE : Evotec Starts Clinical Development of Chikungunya Antibody toget..
DJ
01/28PFIZER INC. : Ex-dividend day for
FA
01/27Pfizer Covid-19 Vaccine Works Against Mutations Found in U.K, South Africa Va..
DJ
01/27PFIZER : Tensions rise as AstraZeneca, EU spar over vaccine delays
AQ
01/27CELCUITY : Unveils Research Collaboration With Sarah Cannon Research Institute, ..
MT
01/27EU Clashes With AstraZeneca Over Covid-19 Vaccine Shortfall
DJ
01/27EU health official blasts slow vaccine delivery, and is consulting with Canad..
AQ
More news
Financials (USD)
Sales 2020 45 929 M - -
Net income 2020 17 722 M - -
Net Debt 2020 42 580 M - -
P/E ratio 2020 14,0x
Yield 2020 4,02%
Capitalization 201 B 201 B -
EV / Sales 2020 5,31x
EV / Sales 2021 4,17x
Nbr of Employees 88 300
Free-Float 59,1%
Chart PFIZER INC.
Duration : Period :
Pfizer Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 41,71 $
Last Close Price 36,24 $
Spread / Highest target 46,2%
Spread / Average Target 15,1%
Spread / Lowest Target -0,66%
EPS Revisions
Managers and Directors
NameTitle
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Suzanne Nora Johnson Independent Director
Helen H. Hobbs Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC.-1.55%201 436
JOHNSON & JOHNSON6.67%441 951
ROCHE HOLDING AG3.62%309 011
NOVARTIS AG0.20%212 810
MERCK & CO., INC.-5.78%194 990
ELI LILLY AND COMPANY22.94%188 179